On March 28, 2022, NeoGenomics Inc. (NASDAQ: NEO) announced disappointing guidance in its quarterly report, as well as the departure of its CEO Mark Mallon.

Following this news, NeoGenomics dropped more than 20% on March 29, 2022, causing harm to investors.

Why is NEO Stock Dropping?

On Monday, March 28, 2022, shares of the health-testing company NeoGenomics dropped sharply after announcing in its quarterly report that Mark Mallon will be stepping down after only a year as company CEO, and that the company will miss guidance and rescind its forecast for the entire year. According to Marketwatch, NeoGenomics’ stock has been slipping since a November report announced disappointing guidance. In the past six months, the company has lost more than 60% of its value, dropping from a market capitalization of $6 billion at times, to around $2.2 billion at market close on Monday March 28th.

According to Investor’s Business Daily, Needham analyst Mike Matson stated the possibility that Mallon invested too much in NeoGenomics minim residual disease test, which searches for cancer in a patient’s blood following treatment. These investments would have affected NeoGenomics’ earnings before interest, taxes, depreciation and amortization, or EBITDA.

Following this news, NeoGenomics’ stock price plummeted more than 20% on March 29, 2022, causing significant harm to investors.

Our Securities Lawyers Have a Winning Record Against Companies Like NeoGenomics

Our securities lawyers have recovered over a billion dollars on behalf of our clients against behemoths, such as Chase Bank, Mastercard, and Anthem Blue Cross Blue Shield. Read more about our results.

You “shouldn’t presume that powerful banks and other powerful interests can just get away with doing bad things. Good, qualified counsel that are committed to a cause can usually figure out how to prosecute such cases effectively and prevail.”

Eric Gibbs, award-winning securities attorney

Praise from the Courts

Federal judge in our AT&T class action:

“I’ve always found them to be extraordinary counsel in terms of their preparation and their professionalism.”

Federal judge in our Chase lawsuit (resulting in $100 million settlement):

They “fought tooth and nail, down to the wire” to achieve “the best settlement that they could under the circumstances.”

Read more about what judges say about us.

Michael Schrag

Michael has over 20 years of experience representing individual and small business plaintiffs against the world’s large financial institutions, including Visa, Mastercard, and Chase.

Eileen Epstein Carney

Eileen works closely with investors in securities cases and has over a decade of experience in the legal world. She received her law degree from American University in 2005.

Dave Stein

David’s advocacy has generated major recoveries for consumers impacted by financial fraud. He was named to the Top 40 Under 40 by Daily Journal and a “Rising Star in Class Actions” by Law360.

Amanda Karl

Amanda is a member of the legal team in a securities lawsuit against NantHealth alleging false statements to investors about the success of its key product.

Gibbs Law Group's Financial Fraud Experience

Gibbs Law Group’s financial fraud and securities lawyers have more than two decades of experience prosecuting fraud. Our attorneys have successfully litigated against some of the largest companies in the United States, and we have recovered more than a billion dollars on our clients’ behalf.

We have fought some of the most complex cases brought under federal and state laws nationwide, and our attorneys have been recognized with numerous awards and honors for their accomplishments, including Top 100 Super Lawyers in Northern California, Top Plaintiff Lawyers in California, The Best Lawyers in America, and rated AV Preeminent (among the highest class of attorneys for professional ethics and legal skills).